Fact-checked by Grok 2 weeks ago

Fibrin glue

Fibrin glue, also known as fibrin sealant, is a biologically derived topical that mimics the final stages of the cascade to form a semi-rigid clot for , tissue sealing, and during surgical procedures. It consists primarily of two components: a fibrinogen concentrate (typically 75-115 mg/, often including Factor XIII) derived from pooled plasma via cryoprecipitation or , and a solution (200-1000 /, now sourced from plasma rather than bovine to reduce immunogenicity risks) combined with to activate clotting. When applied together via dual-syringe systems or aerosolized delivery, cleaves fibrinogen into monomers that polymerize and cross-link via Factor XIIIa, creating a biocompatible gel that adheres tissues, seals leaks, and promotes localized healing without the need for removal due to its biodegradability. First developed and used clinically in 1940 for repair, fibrin glue gained commercial availability in in 1972 and received U.S. FDA approval for products like Tisseel in 1998 as an adjunct for in mild to moderate during , with subsequent expansions including pediatric indications as of 2024. Over decades, its applications have expanded beyond traditional in cardiovascular, thoracic, and orthopedic surgeries—where it reduces blood loss by an average of 161 ml per patient and allogeneic transfusion exposure by 37%—to include sealing cerebrospinal fluid leaks in , preventing formation under skin flaps, and attaching grafts in burn and . In addition to core surgical roles, fibrin glue serves as a versatile vehicle for drug and cell delivery in , enabling controlled release of analgesics like lidocaine for postoperative , antibiotics such as for infection control, chemotherapeutic agents, and growth factors (e.g., VEGF or TGF-β1) to enhance outcomes. Its advantages include reduced operative time, lower recurrence rates in procedures like , and compatibility with sutures as an adjunct, though efficacy can vary by formulation and surgical context, with some studies showing no significant transfusion benefits in certain high-bleeding scenarios.

Overview

Definition

Fibrin glue, also known as , is a biodegradable and biocompatible derived from human plasma proteins that mimics the final stage of the natural cascade by polymerizing fibrinogen into insoluble strands to form a clot-like . This biomaterial serves as a versatile tool in medical practice, functioning primarily as a hemostatic agent to promote clotting, a to close defects, and an to approximate wound edges without the need for sutures. Key physical properties of fibrin glue include a tunable in its fibrinogen component, typically ranging from 18 to 43 mPa·s, which facilitates precise application in surgical settings. It exhibits a rapid setting time of 10 to 60 seconds upon mixing with , allowing for quick adhesion during procedures. The material demonstrates tensile strength up to 10-20 kPa and viscoelastic elasticity akin to soft tissues, enabling it to withstand mechanical stresses while maintaining flexibility. Unlike synthetic glues such as , which are non-biodegradable and can cause or , fibrin glue is of biological origin and undergoes natural resorption via within days to weeks, integrating seamlessly with the body's healing processes. This resorption timeline, often 10-14 days in sites, ensures temporary support without long-term reactions.

History

The concept of using as a hemostatic agent dates back to 1909, when German surgeon Paul Bergel first applied it to control bleeding in surgical wounds. Although fibrinogen had been isolated earlier in the , the development of techniques by Edwin J. Cohn in the 1940s during enabled more reliable production of concentrated fibrinogen from human , laying the groundwork for practical medical applications. The first documented use of as an adhesive came in 1940, when British scientists James Young and employed it to repair peripheral nerves in rabbits, a technique later applied in human to mend war injuries. This marked the shift from rudimentary to targeted tissue adhesion, though early preparations relied on crude extracts prone to inconsistencies and contamination risks. Advancements accelerated in the in , where the first commercial fibrin sealant became available in 1972 and researchers refined formulations to mimic the final stages of the coagulation cascade more effectively. In 1978, introduced Tisseel, an early commercial fibrin sealant, initially approved for in surgical procedures across several European countries. This product combined highly concentrated human ogen and , stabilized with , offering a standardized alternative to autologous methods and expanding applications to broader surgical fields like cardiovascular and . By the early , similar products like Beriplast emerged, further solidifying fibrin glue's role in and prompting global interest despite regulatory hurdles elsewhere. In the United States, adoption lagged due to concerns over viral transmission from human plasma-derived components, particularly in the 1980s, which halted commercial development and confined use to investigational or autologous preparations. The introduction of viral inactivation processes, such as solvent-detergent treatment and vapor heating in the mid-1990s, addressed these safety issues, leading to the FDA's approval of Tisseel in 1998 as the first commercial for topical in specific surgeries like . Further milestones included the 2003 FDA approval of Crosseal (later Evicel) for topical use as a and , and in 2008, expanded European approvals for broader indications including adherence. This era transitioned from experimental, virus-vulnerable extracts to rigorously manufactured, pathogen-reduced products with enhanced safety profiles. Post-2020 research has emphasized autologous fibrin glue variants to further mitigate transfusion-related risks, such as immune reactions and exposure, particularly in high-bleed surgeries like coronary artery bypass grafting. Studies have demonstrated that patient-derived preparations, often combined with , significantly reduce postoperative bleeding without increasing adverse events. These developments reflect ongoing evolution toward personalized, low-risk formulations while building on decades of in production.

Chemistry and Composition

Chemical structure

Fibrinogen, the precursor protein in fibrin glue, is a soluble 340 kDa composed of six polypeptide chains arranged as two identical subunits: Aα, Bβ, and γ chains, interconnected by 29 bonds forming a trinodular with a central E flanked by two outer D . The D domains contain specific sites, including "knobs" in the E domain (A:a and B:b motifs) and complementary "holes" (a in the γ-chain C-terminal domain and b in the β-chain C-terminal domain), which are critical for initiating assembly. Thrombin initiates polymerization by proteolytically cleaving fibrinopeptides A (FpA) from the of the Aα chains and fibrinopeptides B (FpB) from the Bβ chains, thereby exposing the A and B knobs that were previously masked. These exposed knobs bind specifically to the holes in adjacent fibrinogen or molecules, promoting end-to-middle and end-to-end associations that drive the rapid formation of double-stranded protofibrils and their subsequent lateral aggregation into a branching mesh. This process can be summarized by the simplified reaction: \text{Fibrinogen} + \text{Thrombin} \rightarrow \text{Fibrin monomers (knobs exposed)} \rightarrow \text{Insoluble fibrin clot} The resulting fibrin network exhibits a hierarchical architecture, beginning with individual fibrin monomers that assemble into staggered protofibrils, which then bundle laterally to form twisted fibers with diameters typically ranging from 20 to 200 nm, ultimately interconnecting into a porous three-dimensional clot structure. To enhance stability, activated Factor XIII (FXIIIa), a , catalyzes the formation of covalent ε-(γ-glutamyl) isopeptide bonds between the γ-carboxamide group of residues (primarily Gln398/399 in γ-chains) and the ε-amino group of residues (primarily Lys406 in γ-chains) in adjacent fibrin molecules, as well as inter-α chain cross-links, thereby increasing the clot's mechanical strength and resistance to deformation.

Components and formulations

Fibrin glue, also known as fibrin sealant, primarily consists of two core components: a concentrated solution derived from human plasma and a solution, which together mimic the final stages of the natural cascade upon mixing. The component is typically present at concentrations of 50-100 mg/mL to ensure rapid and robust clot formation, while is formulated at 400-625 /mL in products like TISSEEL to catalyze the conversion of to . is included in the solution at approximately 36-44 μmol/mL (~40 μM) to activate XIII and support , with higher concentrations (up to 1200 /mL) used in formulations like EVICEL for quicker setting times in specific applications. Several additives are incorporated to enhance stability and functionality. , a synthetic or bovine-derived agent, is added to some formulations at 2250-3750 KIU/mL to inhibit and prolong clot durability by reducing premature degradation, as seen in TISSEEL. Factor XIII, a naturally present in plasma-derived fibrinogen concentrates, is included at levels of 0.6-5 IU/mL in products like TISSEEL to promote cross-linking of strands, thereby increasing mechanical strength and resistance to shear forces. In plasma-derived versions, trace amounts of (for ) and plasminogen (which can influence if not stabilized) are also retained from the source material, though their levels vary by purification process. Most fibrin glue formulations are designed as two-component systems, delivered via separate syringes or dual-chamber devices that mix the fibrinogen and thrombin solutions at the application site to prevent premature clotting during storage. One-component pre-mixed formulations exist but are less common, relying on inhibitors like GPRP peptides to maintain until , often explored in experimental or patented systems for simplified . Commercial variations differ in sourcing and additives to balance efficacy, safety, and . Human -derived products, such as TISSEEL (containing and XIII) and EVICEL (lacking for reduced allergic risk but with higher ), undergo rigorous purification from pooled donor . Recombinant formulations, using bioengineered human fibrinogen and produced in cell cultures, represent an emerging alternative to eliminate blood-borne pathogen risks entirely, as demonstrated in preclinical totally recombinant human fibrin sealants. Specialized products may include antibiotics or dyes for targeted uses, but core compositions prioritize . To ensure safety, all plasma-derived fibrin glues incorporate multiple viral inactivation steps, achieving reduction factors exceeding 10 log10 for enveloped viruses like and hepatitis C. Common methods include solvent/ treatment (e.g., tri-n-butyl and ) combined with (60°C for 10 hours) for fibrinogen in EVICEL, or vapor alongside solvent/ for both components in TISSEEL, effectively eliminating transmission risks without compromising bioactivity.
Product ExampleFibrinogen (mg/mL)Thrombin (IU/mL)Key AdditivesSource Type
TISSEEL67-106400-625Aprotinin (2250-3750 KIU/mL), Factor XIII (0.6-5 IU/mL), Calcium chloride (36-44 μmol/mL or ~40 μM)Human plasma-derived
EVICEL55-85800-1200Factor XIII (trace), Calcium chloride (in both components)Human plasma-derived
Recombinant prototypesVariable (e.g., 50-100)Variable (e.g., 500)Synthetic Factor XIII optional, no aprotininRecombinant

Production

Autologous methods

Autologous methods for producing involve harvesting and the patient's own to create a personalized , minimizing risks associated with allogeneic products. Typically, 120-350 of is collected from the patient into citrate-anticoagulated tubes or bags. The undergoes initial at 580-3000 rpm for 3-10 minutes to separate from cellular components. For fibrinogen isolation, the is often subjected to cryoprecipitation: freezing at -18°C to -80°C followed by slow thawing at 4°C for 1-2 hours, then at 1000-5000 rpm for 5-20 minutes to yield a rich in fibrinogen, typically at concentrations of 10-47 mg/ depending on the precipitation technique. Alternative methods include direct use or chemoprecipitation with agents like or to concentrate fibrinogen, achieving yields of 3-50 mg/ from smaller volumes (36-140 ). The is then washed, resuspended in buffer (e.g., at 7.4), and stored briefly at 4°C if needed. Thrombin generation in autologous preparations avoids exogenous sources by activating the patient's prothrombin. Common approaches include adding calcium chloride or gluconate (1:1 to 1:5 ratios) to plasma or cryoprecipitate, incubating at 37°C for 15-60 minutes to release thrombin endogenously. Alternatively, batroxobin (a snake venom-derived enzyme) is used in systems like Vivostat: plasma is incubated with batroxobin at 37°C for 10 minutes to cleave fibrinogen into fibrin I monomers, followed by filtration to remove the enzyme. The fibrinogen and thrombin components are mixed at ratios of 1:1 to 1:10 just prior to application, often via dual-syringe delivery systems, resulting in polymerization within 2-30 seconds. Clotting time can be tailored by adjusting thrombin concentration or calcium levels, allowing customization from 5-30 seconds for specific procedural needs. These methods leverage equipment such as standard centrifuges, kits, and automated processors like the Vivostat , which completes preparation in 30-60 minutes from a single blood draw. Advantages include zero risk of transmission or immunological due to the autologous nature, enhanced , and suitability for on-site customization in procedures like cardiac or . However, limitations persist, such as variability in fibrinogen yield (5-50 mg/mL influenced by patient factors like age or health), potential inconsistencies in activity, and extended preparation times (30-60 minutes) compared to pre-made alternatives.

Commercial manufacturing

Commercial manufacturing of fibrin glue relies on industrial-scale processing of pooled human plasma sourced from rigorously screened donors at licensed collection centers. Batches typically incorporate thousands of plasma units to achieve economies of scale and product consistency, with donors undergoing testing for infectious diseases such as , and C, and . The fibrinogen component is isolated and concentrated via cryoprecipitation, where plasma is frozen at -20°C to -80°C and slowly thawed at 0-4°C to precipitate fibrinogen, Factor XIII, and , resulting in concentrations of 80-120 mg/mL after further purification. Thrombin production begins with activation of prothrombin from human , with bovine sources largely phased out to minimize risks, achieving greater than 95% purity through chromatographic purification. and stabilizing buffers, such as or , are added to the solution (typically 400-625 /mL) to optimize activity and shelf-life. The overall process employs via the modified Cohn method to separate proteins into fractions, followed by inactivation steps including / treatment (e.g., tri-n-butyl phosphate and Tween 80) and vapor heat at 60°C for 10 hours. Nanofiltration with 20-35 nm pore-size filters provides an additional barrier against enveloped and non-enveloped viruses, achieving factors exceeding 12 for pathogens like HIV-1 and . Final formulation involves mixing the fibrinogen (sealer protein) solution with or synthetic , and the solution, under aseptic conditions, then sterile filling into pre-loaded dual-syringe delivery systems for immediate clinical use. complies with FDA and guidelines, mandating potency specifications of fibrinogen greater than 70 mg/mL and greater than 400 IU/mL, validated against WHO international standards, alongside tests for sterility (no microbial growth per USP <71>) and endotoxin levels below 0.5 EU/mL via assay. Annual global production reaches several tons of fibrinogen concentrate to meet demand, exemplified by brands like Artiss, which uses synthetic to eliminate bovine-derived allergens and reduce risks. This donor-based approach contrasts with autologous methods by providing ready-to-use, virus-inactivated products for broad surgical applications.

Pharmacology

Mechanism of action

Fibrin glue initiates clotting through the enzymatic action of , which cleaves fibrinopeptides A and B from the N-terminal regions of fibrinogen molecules. This cleavage exposes polymerization knobs in the central E domain (specifically, A-knobs from Gly-Pro-Arg sequences and B-knobs from Gly-His-Arg-Pro sequences) that bind to complementary holes in the D domains of adjacent molecules (a-holes in γ-nodules and b-holes in β-nodules). These knob-hole interactions, primarily driven by A:a bonds, lead to the end-to-middle and end-to-end assembly of fibrin monomers into double-stranded protofibrils, which further aggregate laterally to form a branched, three-dimensional fibrin network. Cross-linking of the network is mediated by factor XIII, which is activated by in the presence of calcium ions. Activated factor XIIIa catalyzes the formation of covalent isopeptide bonds, initially between the γ-chains of adjacent fibrin molecules and subsequently between α-chains, creating a stabilized, insoluble clot structure. This cross-linking process enhances the mechanical properties of the fibrin gel, increasing its by 2- to 5-fold and significantly improving resistance to shear and . Adhesion of the fibrin clot to tissues occurs through mechanical interlocking and biochemical interactions, with the fibrin network providing a provisional scaffold that supports platelet aggregation and cellular infiltration. If fibronectin is present in the formulation, its covalent cross-linking to by factor XIIIa exposes integrin-binding sites (such as the RGD motif), which promote cell attachment and spreading via like α5β1 and αvβ3, facilitating ingrowth and repair. The time course of fibrin glue action depends on concentration: gelation typically occurs within 10-90 seconds, with higher concentrations (e.g., 500-1000 /mL) accelerating initial , while full cross-linking and clot strength develop over 5-10 minutes under applied pressure. The overall process can be represented as: \text{Fibrinogen (soluble)} + \text{[Thrombin](/page/Thrombin)/Ca}^{2+} \rightarrow \text{Protofibril formation} \rightarrow \text{Factor XIII} \rightarrow \text{Cross-linked [fibrin](/page/Fibrin) (insoluble clot)}

Fibrin glue components demonstrate minimal systemic following topical application, as the material is designed for localized use with no significant exposure expected in or distant tissues. In animal models, such as rats receiving pulmonary application of labeled fibrinogen, radioactivity remained predominantly at the site, with only trace detection in organs like the liver and kidneys on days 1 and 3 post-application. Peak levels of fibrinogen-derived radioactivity at the site occur within hours, aligning with observations of 1.8–5.7 hours in related intraperitoneal models, though topical routes further limit uptake. Distribution is highly localized to the application site, where the formed clot confines , , and other components, preventing widespread dissemination. Excess is rapidly adsorbed by the matrix or inactivated by endogenous inhibitors, with beyond the clot boundary typically restricted due to the dense structure. Systemic distribution is negligible in topical scenarios, as confirmed by pharmacokinetic studies showing no notable accumulation in non-target organs. The primary metabolic pathway for fibrin glue involves degradation via the fibrinolytic system, where cleaves into soluble fragments and other breakdown products. This process mimics natural clot resolution, with the matrix undergoing and over time. The of the clot ranges from 2 to 14 days , influenced by local tissue factors; degradation accelerates in highly vascularized areas due to elevated concentrations and blood flow. Commercial formulations often incorporate , a inhibitor that extends clot stability compared to unmodified versions. Elimination of fibrin glue breakdown products occurs predominantly through renal clearance, with and its metabolites exhibiting a short of 30–60 minutes and rapid kidney . Soluble fragments, including D-dimers, follow similar renal pathways without of accumulation in healthy patients. Autologous fibrin glues, derived from patient without added stabilizers like aprotinin, exhibit faster degradation rates due to individual variations in endogenous fibrinolytic enzymes.

Medical Uses

Surgical applications

Fibrin glue serves as an effective hemostatic agent in various surgical procedures, particularly for controlling diffuse in liver and . In hepatic , it achieves after one or two applications even in the presence of and , promoting rapid clot formation at the injury site. A 2012 systematic and of randomized controlled trials demonstrated its haemostatic and biliostatic capacity in elective liver , significantly reducing intraoperative blood loss compared to standard techniques. In cardiovascular , fibrin glue enhances on native and prosthetic arterial anastomoses, improving outcomes in vascular procedures by minimizing from suture lines. In sealing applications, fibrin glue is commonly employed to close air leaks during surgery, such as in the management of bronchial fistulas following . Aerosolized application reduces the incidence of prolonged air leaks by up to 50% and limits recurrence rates to less than 5% in prospective studies. In , it provides watertight closure of the , preventing (CSF) leaks after repairs; a systematic reported overall success rates of 90% in high-risk cases, with reduced postoperative complications when used as an adjunct to suturing. For adhesion purposes, fibrin glue secures skin grafts in burn surgery, improving take rates to approximately 90% without the need for staples or sutures, as evidenced by phase 3 clinical trials showing median graft adherence of 95% and reduced slippage. In hernioplasty, it facilitates sutureless mesh fixation, leading to lower rates of postoperative and recurrence compared to traditional suturing, according to meta-analyses of randomized trials. Specific procedures benefiting from fibrin glue include ophthalmic surgeries like corneal transplants, where it enables sutureless lamellar keratoplasty, reducing operative time and risk while providing secure donor-recipient adhesion. In ear, nose, and throat (ENT) interventions, such as repairs via , fibrin glue enhances graft stability and success rates in fat without the use of discs. Despite these benefits, fibrin glue has limitations in high-pressure vascular applications, where it risks if applied to actively large vessels, potentially leading to systemic complications; it is contraindicated in such scenarios to avoid dislodgement by flow.

Non-surgical uses

Fibrin glue is utilized in non-surgical management for chronic ulcers, including ulcers, where topical application promotes and tissue to facilitate . A randomized involving patients with non-healing ulcers demonstrated that platelet-rich plasma-fibrin glue dressings, combined with oral vitamins E and C, significantly enhanced closure rates and reduced time compared to controls receiving standard care alone. In fistula closures, such as vesicovaginal s, fibrin glue injection offers a minimally invasive alternative, though a 2025 of clinical studies found no superiority in achieving successful closure rates over traditional suturing with interpositional flaps. In , fibrin glue acts as a biocompatible to support cell delivery and retention in procedures like autologous implantation for repair. A 2023 study evaluated the adhesive and frictional properties of commercial fibrin sealants for repair, reporting tensile and shear strengths below levels typically desired for secure fixation of membranes in focal defects. Similarly, in dental , fibrin glue implants seeded with dental pulp and periodontal ligament cells have shown promise for regenerating tooth structures by providing a supportive matrix that mimics the extracellular and promotes . Beyond human applications, fibrin glue is employed in endoscopic for variceal bleeding, where injection achieves rapid . Clinical evaluations indicate that fibrin glue is an efficient and safe agent for controlling acute bleeding from , particularly in emergency settings, by forming a stable clot without the embolization risks associated with synthetic glues. In , it has been applied for non-surgical treatments such as canine aural hematomas and post-intubation tracheal lacerations in cats, highlighting its adaptability for animal closure and sealing. Emerging focuses on integrating fibrin glue with advanced hydrogels to create self-healing dressings capable of sustained therapeutic release. A 2024 study on oxidized polysaccharide-modified fibrin hydrogels demonstrated improved water retention, controlled degradation, and enhanced , supporting prolonged delivery of growth factors for repair. For pilonidal , evidence remains limited, with a 2017 Cochrane review noting potential benefits as an adjunct to but no significant advancements or superior outcomes reported in studies up to 2025. Recent trials from 2020 to 2025 exploring fibrin glue combinations with for , particularly in diabetic ulcers, have yielded inconsistent results. While some randomized studies reported accelerated closure through enhanced and reduced , others observed variable efficacy influenced by patient comorbidities and preparation methods, underscoring the need for standardized protocols.

Administration

Techniques

Fibrin glue is typically delivered using dual-syringe applicators that enable simultaneous dispensing and on-site mixing of the fibrinogen and components, ensuring immediate clot formation upon application. These systems, such as the Duploject device, allow for precise control over the application, with options for drop-by-drop delivery to localized areas or spray mechanisms for broader coverage, with typical volumes covering 100-500 cm² depending on product and volume applied. In minimally invasive procedures, specialized laparoscopic delivery devices facilitate targeted application through small incisions, adapting the dual-syringe format to endoscopic ports for enhanced precision in confined spaces. The standard application process begins with thorough debridement and drying of the target tissue surface to optimize and prevent dilution of the . The components are then mixed at the application site, typically in a thrombin-to-fibrinogen volume ratio of 1:1, though adjustable ratios up to 1:5 may be used depending on the desired clot strength and . Once applied as a thin layer via or spraying, manual is exerted on the site for 1-2 minutes to facilitate integration with the tissue and initial clot stabilization, with full setting occurring shortly thereafter. Specialized techniques adapt these methods for specific procedural contexts, such as endoscopic injection where dual-lumen catheters deliver the mixed directly into fistulas or leaks in volumes suited to the tract size, often requiring sequential component injection to avoid premature clotting within the device. In , robotic-assisted spraying employs articulated arms to apply the sealant precisely over anastomotic sites, minimizing manipulation and enabling uniform coverage in dynamic operative fields. Best practices emphasize maintaining component temperatures between 20-37°C during preparation and application to ensure optimal and avoid thermal denaturation, which could impair efficacy. Application should form a thin, even layer to prevent pooling, as thicker accumulations may lead to uneven clots with reduced tensile strength; additionally, the applicator tip must be positioned at least 2 cm from the tissue to achieve consistent spray patterns without tissue damage. Variations in delivery include manual dispensers for fine control in open surgeries versus automated systems that regulate flow rates for , with the Duploject exemplifying an integrated approach that combines and application in a single unit to streamline workflow. These adaptations allow tailoring to procedural demands, such as combining spraying with rubbing techniques to enhance penetration into irregular surfaces.

Dosage considerations

Fibrin glue dosages are determined primarily by the size of the or surface area to be treated, with volumes ranging from 2 mL for small areas (covering approximately 8-22 cm² via or 100 cm² via spray) to 10 mL for larger surfaces (up to 500 cm² via spray). For example, in applications like liver lacerations, volumes of 4-10 mL may be used to achieve over extensive areas, applied as a thin layer to avoid excess buildup. Concentrations of key components vary by product formulation to suit specific needs, with fibrinogen typically at 55-106 mg/ and thrombin ranging from 2.5-6.5 / for slower-setting glues used in tissue approximation to 400-1200 / for rapid hemostasis. Higher thrombin concentrations enable setting times under 10 seconds, ideal for brisk bleeding, while lower levels (e.g., 4 /) extend polymerization to 1-3 minutes for delicate tissues like the cornea, minimizing pressure and allowing better adherence. Regulatory guidelines recommend dosing based on surface coverage rather than fixed maximums, though kits are typically limited to 10 mL per procedure to prevent overuse; pediatric applications follow adult protocols scaled to body surface, with mean volumes around 4.6 mL reported in neonates to adolescents. Effective dosing requires visual confirmation of clot formation within 2-3 minutes post-application, with re-application of additional thin layers if incomplete coverage is observed after 5 minutes. In fibrinolysis-prone areas, such as vascular or peritoneal sites, reduced doses combined with (2250-3750 KIU/mL in select formulations) enhance stability by inhibiting premature breakdown, though aprotinin-containing products are avoided in hypersensitive patients.

Safety Profile

Contraindications

Fibrin glue is contraindicated for intravascular administration due to the risk of life-threatening thromboembolic complications and (). This absolute prohibition stems from the potential for the sealant to trigger widespread clotting if introduced into the bloodstream, as evidenced by product labeling and clinical warnings across formulations. Known to components of the fibrin glue represents another absolute contraindication. For products containing bovine-derived elements, such as or , individuals with prior or severe reactions to bovine proteins must avoid use, as allergic responses including , wheezing, or can occur. Similarly, for human plasma-derived sealants, a history of severe systemic reactions to human blood products precludes application. reactions are rare but can be more frequent with repeated exposures. Additionally, fibrin glue should not be used to control massive or brisk arterial bleeding, as high blood flow may prevent adequate adhesion and . Relative contraindications include active or at the application site, where the sealant could exacerbate bacterial spread or promote formation by sealing pathogens within tissues. In patients with coagulopathies, such as hemophilia, use requires caution due to potential unpredictable clotting responses, though it has been employed as an adjunct in some cases. Recent fibrinolytic therapy, including tissue plasminogen activator (tPA) within 48 hours, may impair efficacy by accelerating of the formed clot. Among special populations, fibrin glue carries relative risks in , classified as Category C due to limited data and unknown fetal effects, though show no direct harm. Neonates present challenges owing to their immature systems, with reduced levels potentially affecting sealant performance and increasing bleeding or risks. In October 2024, the FDA approved fibrin sealant for use in pediatric patients aged 1 month and older for , with studies showing a favorable profile comparable to adults. Patients with alpha-2-antiplasmin deficiency may experience heightened , rendering the sealant less stable and raising concerns for inadequate or dehiscence. Overall, these contraindications aim to mitigate risks of , , allergic events, or failure.

Side effects

Fibrin glue use is generally associated with a low incidence of adverse reactions, primarily due to its biological components derived from human plasma. Common side effects include local at the application site, fever, and transient . These reactions are typically mild and self-limiting, often resolving without intervention. Additionally, if sterility is not maintained during preparation or application, the risk of wound can arise, though proper aseptic techniques mitigate this concern. Serious adverse events are infrequent, affecting less than 1% of cases. , manifesting as urticaria, , or , has been linked primarily to the component in certain formulations, with an estimated incidence of 0.03-0.5 per 100,000 applications upon re-exposure. Thromboembolic complications, such as pulmonary emboli, occur rarely when used as directed, with no significant increase in risk compared to standard surgical procedures. Transmission of undetected viruses remains a theoretical concern with plasma-derived products, but post-2000 enhancements in donor screening and viral inactivation processes have reduced the incidence to less than 1 in 10^6 units, with no confirmed cases of or transmission in over 20 years of commercial use. Rare complications include antibody formation against fibrinogen or , potentially leading to autoimmune-like reactions, and delayed responses such as appearing 24-48 hours post-application. These events are exceedingly uncommon, with fewer than 10 documented cases in neurosurgical applications since 1987. Management of allergic reactions involves immediate of epinephrine and supportive care, while all patients should undergo for at least 24 hours following to detect any delayed effects. Post-2020 data indicate reduced allergy rates with aprotinin-free formulations like Evicel, where severe occurs in up to 1 in 1,000 cases, compared to higher risks with aprotinin-containing products; this improvement stems from eliminating the allergenic stabilizer while maintaining efficacy. Patients with known to should avoid such formulations, as detailed in contraindications.

Interactions

Fibrin glue can be denatured upon contact with certain antiseptics, including , iodine, and ions commonly found in preparations. These substances interfere with the process essential for clot formation, potentially rendering the ineffective if applied in proximity to such agents. For instance, like silver in formulations have been noted to disrupt fibrin cross-linking when combined directly, though clinical use in management has explored their integration in matrices without complete inhibition. Pharmacologically, fibrin glue exhibits significant interactions with fibrinolytics such as and , which accelerate its degradation by activating plasminogen to , leading to rapid clot lysis often within less than one hour. Anticoagulants like also affect fibrin glue by prolonging the setting time through inhibition of activity, which delays fibrinogen conversion to and may compromise immediate in surgical settings. Biologically, concomitant use of fibrin glue with (PRP) enhances adhesion strength and mechanical properties of the resulting clot due to the additional growth factors and platelets that promote fibrin cross-linking and integration. However, this increases the risk of over-clotting and excessive in vascular applications. In contrast, certain antibiotics, such as aminoglycosides like gentamicin, demonstrate compatibility with fibrin glue, maintaining activity without substantially impairing clot rigidity or , allowing for sustained local drug release. Procedurally, exposure of fibrin glue components to air or oxygen during application can induce foaming of the mixture, resulting in uneven clot formation and weakened bonds that reduce overall . Additionally, extreme environments below 6 or above 8 inhibit activity, preventing proper fibrinogen activation and monomer assembly, which underscores the need for neutral conditions during preparation and use. These interactions necessitate careful clinical management, such as applying fibrin glue prior to antiseptics or adjusting timing around fibrinolytics to preserve . Recent studies from 2023 indicate no major adverse interactions when fibrin glue is combined with modern biologics like adipose-derived stem cells in dermal replacement therapies, supporting its safe integration in regenerative applications.

Legal and Regulatory Aspects

Approval history

Fibrin glue, also known as fibrin sealant, received its initial commercial regulatory approvals in Europe in the late 1970s for hemostatic use, with products like Tissucol (now known as Tisseel in some markets) among the early authorized commercial formulations. This early approval facilitated widespread adoption in surgical settings across the European Union, focusing on adjunctive hemostasis during procedures where conventional methods were ineffective or impractical. In contrast, development in the United States faced significant delays due to concerns over viral transmission risks from plasma-derived components, leading to investigational use only during the 1980s while stringent safety standards were established. The U.S. (FDA) granted full approval for Tisseel in May 1998 as a topical for non-pyrogenic in specific surgeries, including , colon resection (including sealing to prevent leakage from colonic anastomoses following reversal of temporary colostomies), and splenic trauma. This marked the first commercial licensed in the U.S., emphasizing inactivation processes to mitigate risks. An expansion in 2003 extended approvals to additional formulations, such as Crosseal, for broader hemostatic applications in liver , further solidifying its role in controlling mild to moderate . Subsequent expansions broadened indications for sealing and adhesion. In 2008, the () authorized Evicel, a human-derived fibrin sealant, for tissue sealing during vascular and pulmonary surgeries. The FDA followed with approvals for aprotinin-free versions, including Artiss in March 2008 for adhering skin grafts in burn patients, addressing prior allergy concerns associated with aprotinin-stabilized products like earlier Tisseel formulations. Updates from 2020 to 2025 focused on refined aprotinin-free compositions and sprayable delivery systems, enhancing safety profiles amid ongoing post-market surveillance for . In September 2025, the FDA approved supplements expanding Tisseel and Artiss indications to adjunct in adult and pediatric patients undergoing surgery when standard techniques are ineffective. Regulatory milestones were supported by pivotal clinical trials demonstrating safety and efficacy. Phase III randomized controlled trials in the 1990s, including those preceding Tisseel's U.S. approval, reported low adverse event rates, with infection incidences below 1% in hemostatic applications across cardiovascular and general surgeries. More recent evaluations, such as a 2022 randomized controlled trial protocol for burn wound management, confirmed fibrin sealant's role as an adjunct in promoting graft adherence and reducing hematoma formation without increased infection risks. Internationally, fibrin glue achieved approval in through the (PMDA) in the late 1970s for hemostatic use in surgical bleeding control. These global approvals addressed earlier gaps from the HIV era, where U.S. and some international markets imposed bans on plasma-derived products from 1987 to 1998 due to transmission fears; advancements in inactivation technologies, such as solvent-detergent treatment and nanofiltration, enabled safe reintroduction by ensuring no documented cases of or transmission in commercial products.

Global status

In the United States, fibrin glue products such as Evicel and Tisseel are FDA-approved for multiple indications, including in surgical procedures where conventional methods are ineffective or impractical. These biologics are available by prescription only and are covered by Part B for outpatient surgical uses and Part A for inpatient settings when deemed medically necessary. In , fibrin sealants have received centralized approvals for various products, with Evicel authorized in 2008 (though its marketing was withdrawn in July 2024 for reasons) and VeraSeal approved in November 2017, making them widely available across member states through national authorizations and CE-marked as medical devices. Elsewhere, fibrin glue gained approval from in 2014 for products like Evicel and Vistaseal, from Australia's in March 2009 for Tisseel, and in via CDSCO in June 1996 for Beriplast with subsequent generic versions entering the market. Access remains restricted in some developing countries primarily due to high costs, with kits priced between $100 and $500, limiting adoption in resource-constrained healthcare systems. The global market for fibrin glue reached approximately $639 million in sales during 2024, dominated by major manufacturers and (a subsidiary), which together hold a significant share through branded products like Tisseel and Evicel. Autologous fibrin sealant systems, derived from patient blood to minimize risks, are experiencing annual growth of around 10% amid rising demand for personalized therapies. Worldwide, fibrin glue is restricted from intravascular use due to the risk of and if inadvertently injected into blood vessels, a emphasized in all product labels and regulatory guidelines. As of 2025, recombinant variants are emerging in , particularly in , to reduce risks associated with human-derived components and enhance safety profiles.